7C01
Molecular basis for a potent human neutralizing antibody targeting SARS-CoV-2 RBD
Experimental procedure
Experimental method | SINGLE WAVELENGTH |
Source type | SYNCHROTRON |
Source details | SSRF BEAMLINE BL17U1 |
Synchrotron site | SSRF |
Beamline | BL17U1 |
Temperature [K] | 100 |
Detector technology | PIXEL |
Collection date | 2020-03-22 |
Detector | DECTRIS EIGER X 16M |
Wavelength(s) | 0.97919 |
Spacegroup name | P 21 21 21 |
Unit cell lengths | 87.400, 106.730, 170.590 |
Unit cell angles | 90.00, 90.00, 90.00 |
Refinement procedure
Resolution | 34.830 - 2.880 |
R-factor | 0.2204 |
Rwork | 0.218 |
R-free | 0.26510 |
Structure solution method | MOLECULAR REPLACEMENT |
Starting model (for MR) | 6lgz 4tsa |
RMSD bond length | 0.004 |
RMSD bond angle | 0.776 |
Data reduction software | HKL-2000 |
Data scaling software | HKL-2000 |
Phasing software | PHASER |
Refinement software | PHENIX (1.15.2_3472) |
Data quality characteristics
Overall | Outer shell | |
Low resolution limit [Å] | 50.000 | 2.950 |
High resolution limit [Å] | 2.880 | 2.880 |
Number of reflections | 36863 | 2670 |
<I/σ(I)> | 12.2 | |
Completeness [%] | 99.9 | |
Redundancy | 13 | |
CC(1/2) | 0.997 | 0.640 |
Crystallization Conditions
crystal ID | method | pH | temperature | details |
1 | VAPOR DIFFUSION, SITTING DROP | 291 | 24 % w/v PEG 1500, 20 % v/v Glycerol |